Cibc World Markets Corp Boosts Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Cibc World Markets Corp grew its holdings in West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 133.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,522 shares of the medical instruments supplier’s stock after purchasing an additional 5,445 shares during the quarter. Cibc World Markets Corp’s holdings in West Pharmaceutical Services were worth $3,353,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in WST. Planned Solutions Inc. purchased a new position in shares of West Pharmaceutical Services in the fourth quarter valued at approximately $39,000. Addison Advisors LLC lifted its stake in West Pharmaceutical Services by 28.9% in the fourth quarter. Addison Advisors LLC now owns 183 shares of the medical instruments supplier’s stock worth $64,000 after acquiring an additional 41 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its stake in West Pharmaceutical Services by 90.0% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 190 shares of the medical instruments supplier’s stock worth $67,000 after acquiring an additional 90 shares during the last quarter. Lindbrook Capital LLC lifted its stake in West Pharmaceutical Services by 46.0% in the fourth quarter. Lindbrook Capital LLC now owns 235 shares of the medical instruments supplier’s stock worth $83,000 after acquiring an additional 74 shares during the last quarter. Finally, Tompkins Financial Corp purchased a new position in West Pharmaceutical Services in the fourth quarter worth approximately $89,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Down 0.2 %

Shares of NYSE:WST opened at $314.68 on Friday. The company has a market capitalization of $22.92 billion, a PE ratio of 41.51, a P/E/G ratio of 5.56 and a beta of 1.01. The company has a current ratio of 2.61, a quick ratio of 1.95 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a twelve month low of $310.42 and a twelve month high of $415.73. The firm has a 50 day simple moving average of $359.68 and a 200-day simple moving average of $362.56.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.27. The business had revenue of $695.40 million during the quarter, compared to the consensus estimate of $670.62 million. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The company’s revenue was down 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.98 EPS. On average, equities analysts predict that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Stockholders of record on Wednesday, July 31st will be issued a $0.20 dividend. The ex-dividend date of this dividend is Wednesday, July 31st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.25%. West Pharmaceutical Services’s payout ratio is 10.55%.

Wall Street Analyst Weigh In

WST has been the subject of a number of recent research reports. KeyCorp lifted their price target on shares of West Pharmaceutical Services from $440.00 to $470.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 13th. StockNews.com downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Friday, February 16th. Finally, UBS Group decreased their price target on shares of West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating for the company in a research note on Friday, February 16th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $435.20.

Read Our Latest Stock Report on WST

Insider Activity

In other news, CAO Chad Winters sold 815 shares of West Pharmaceutical Services stock in a transaction on Monday, March 11th. The shares were sold at an average price of $358.82, for a total value of $292,438.30. Following the transaction, the chief accounting officer now directly owns 1,309 shares of the company’s stock, valued at approximately $469,695.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total value of $24,198,900.00. Following the transaction, the chief executive officer now directly owns 152,908 shares of the company’s stock, valued at approximately $56,063,718.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Chad Winters sold 815 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $358.82, for a total transaction of $292,438.30. Following the completion of the transaction, the chief accounting officer now directly owns 1,309 shares in the company, valued at $469,695.38. The disclosure for this sale can be found here. Corporate insiders own 0.53% of the company’s stock.

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Read More

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.